Effect of Iptacopan on Complement and Inflammatory Biomarkers in IgAN: Final 24-Month Results of the Phase 3 APPLAUSE-IgAN Study (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-OR065; Pres time: Oct 23, 2026; 04:40 PM - 04:50 PM; Location: Room 501, Convention Center; P3 | "As expected from iptacopan's proposed mechanism of action, Gd-IgA1 was not affected. The reduction in urinary sCD163 suggests that iptacopan also attenuates glomerular inflammation in patients with IgAN."
Biomarker • P3 data • Glomerulonephritis • IgA Nephropathy • Inflammation • Renal Disease
|
|
Dana V. Rizk; Vlado Perkovic; Jonathan Barratt; Hernan Trimarchi; Bart D. Maes; Naoki Kashihara; Hong Zhang; Shiuli Agarwal; Imelda Schuhmann; Dyuti Coomar; Lindsay Govan; Emanuela Gardenal; Thomas Hach; Manasi Mital Desai; Brad Rovin
|